1-环己基-3'-十二烷基脲 | 402939-18-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 1-环己基-3'-十二烷基脲
• 英文名称: 1-cyclohexyl-3-dodecyl urea
• 英文别名: 1-cyclohexyl-3-dodecylurea；CDU；N-cyclohexyl-N'-dodecyl urea；N-cyclohexyl-N'-dodecylurea
• CAS: 402939-18-8
• 化学式: C₁₉H₃₈N₂O
• 分子量: 310.524
• InChiKey: POEWFBSYPFIYSK-UHFFFAOYSA-N

物化性质

• 沸点：
  465.1±12.0 °C(Predicted)
• 密度：
  0.92±0.1 g/cm3(Predicted)
• 溶解度：
  乙醇：16.67 mg/mL（53.68 mM）

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  22
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 储存条件：
  2-8℃

制备方法与用途

生物活性

1-环己基-3-十二烷基脲 (CDU，N-环己基-N-十二烷基脲，NCND) 是一种高选择性的可溶性环氧酶水解酶 (sEH) 抑制剂，能增加环氧二十碳三烯酸 (EETs) 的表达水平。

靶点

Target	Value
sEH	()

体内研究

1-环己基-3-十二烷基脲 (CDU；N-环己基-N-十二烷基脲；NCND)（腹腔注射，3 mg/天，4 天）能显著降低血管紧张素 II 引起的高血压动物的收缩压 30 mm Hg，而玉米油对照组对正常血压或血管紧张素 II 引起的高血压动物的血压无影响。

实验结果：

• 动物模型：雄性SD大鼠
• 剂量：3 mg/天
• 给药方式：腹腔注射，4 天
• 结果：具有降压作用。

反应信息

• 作为产物：
  描述：

  十二烷基伯胺 、 环己基异氰酸酯 以 正己烷 为溶剂， 反应 1.0h， 以97%的产率得到1-环己基-3'-十二烷基脲
  参考文献：
  名称：

  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases

  摘要：

  The soluble epoxide hydrolase (sEH) is involved in the metabolism of arachidonic, linoleic, and other fatty acid epoxides, endogenous chemical mediators that play an important role in blood pressure regulation and inflammation. 1,3-Disubstituted ureas, carbamates, and amides are new potent and stable inhibitors of sEH. However, the poor solubility of the lead compounds limits their use. Inhibitor structure-activity relationships were investigated to better define the structural requirements for inhibition and to identify points in the molecular topography that could accept polar groups without diminishing inhibition potency. Results indicate that lipophilicity is an important factor controlling inhibitor potency. Polar groups could be incorporated into one of the alkyl groups without loss of activity if they were placed at a sufficient distance from the urea function. The resulting compounds had a 2-fold higher water solubility. These findings will facilitate the rational design and optimization of sEH inhibitors with better physical properties. (C) 2002 Published by Elsevier Science Inc.

  DOI：

  10.1016/s0006-2952(02)00952-8

文献信息

• Inhibitors for the soluble epoxide hydrolase
  申请人：Hammock D. Bruce

  公开号：US20050164951A1

  公开（公告）日：2005-07-28

  Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

  提供了抑制可溶性环氧化酶（sEH）的抑制剂，这些抑制剂结合了多个药效团，在治疗疾病方面非常有用。
• Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils
  申请人：Hammock D. Bruce

  公开号：US20050222252A1

  公开（公告）日：2005-10-06

  It has now been discovered that inhibitors of soluble epoxide hydrolase (“sEH”) are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosantrienoic acid (“EET”) in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced numbers of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.

  现在已经发现，可溶性环氧酰胺水解酶（“sEH”）的抑制剂对于减轻或抑制阻塞性肺疾病、限制性气道疾病和哮喘的严重程度是有用的。在抑制剂的基础上给予顺式环氧二十碳五烯酸（“EET”）至少是具有相加作用的，并且可能具有协同作用，可通过减少肺部中嗜中性粒细胞数量来减轻或抑制这些状况和疾病。sEH的抑制剂可能是核酸，例如小干扰RNA。
• [EN] 18F-FNDP FOR PET IMAGING OF SOLUBLE EPOXIDE HYDROLASE (sEH)<br/>[FR] 18F-FNDP POUR L'IMAGERIE TEP D'ÉPOXYDE HYDROLASE SOLUBLE (EHS)
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2017192854A1

  公开（公告）日：2017-11-09

  Radiofluorinated FNDP for PET imaging of soluble epoxide hydrolase (sEH) and method of using the same are disclosed.

  本发明揭示了用于正电子发射断层扫描(sEH)的可溶性环氧水解酶的放射性氟标记FNDP，以及使用该方法的方法。
• METHODS OF TREATING AVIAN HYPERTENSION
  申请人：Hammock Bruce D.

  公开号：US20080188554A1

  公开（公告）日：2008-08-07

  The present invention provides methods of treating avian pulmonary hypertension syndrome by administering to an avian subject a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase (“sEHI”), alone or co-administered in combination with a cis-epoxyeicosantrienoic acid (“EET”). The invention also provides nucleic acid and amino acid sequences of an avian soluble epoxide hydrolase.

  本发明提供了治疗禽类肺高血压综合症的方法，通过向禽类主体投与可治疗量的可溶性环氧酶抑制剂（“sEHI”），单独或联合使用顺式环氧二十碳三烯酸（“EET”）。本发明还提供了禽类可溶性环氧酶的核酸和氨基酸序列。
• INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE
  申请人：Hammock Bruce D.

  公开号：US20090326039A1

  公开（公告）日：2009-12-31

  Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

  提供了可用于治疗疾病的可溶性环氧水解酶（sEH）的抑制剂，其中包含多个药效团。